Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Clin Cancer Res (2021) 27 (16): 4491–4499.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-0611

Published: 15 August 2021

View article

Includes: Supplementary data

Journal Articles

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Clin Cancer Res (2021) 27 (10): 2723–2733.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-4256

Published: 15 May 2021

View article

Includes: Supplementary data

Journal Articles

Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor−positive Metastatic Breast Cancer or Other Solid Tumors

Alexej Ballhausen, Jennifer J. Wheler, Daniel D. Karp, Sarina A. Piha-Paul, Siqing Fu, Shubham Pant, Apostolia M. Tsimberidou, David S. Hong, Vivek Subbiah, Veronica R. Holley, Helen J. Huang, Abenaa M. Brewster, Kimberly B. Koenig, Nuhad K. Ibrahim, Funda Meric-Bernstam, Filip Janku

Clin Cancer Res (2021) 27 (5): 1247–1255.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-2878

Published: 01 March 2021

View article

Journal Articles

Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors

Clin Cancer Res (2021) 27 (1): 96–106.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-2065

Published: 04 January 2021

View article

Includes: Supplementary data

Journal Articles

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Clin Cancer Res (2020) 26 (21): 5579–5587.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-1215

Published: 02 November 2020

View article

Includes: Supplementary data

Journal Articles

Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer

Seyed Pairawan, Kenneth R. Hess, Filip Janku, Nora S. Sanchez, Kenna R. Mills Shaw, Cathy Eng, Senthilkumar Damodaran, Milind Javle, Ahmed O. Kaseb, David S. Hong, Vivek Subbiah, Siqing Fu, David R. Fogelman, Victoria M. Raymond, Richard B. Lanman, Funda Meric-Bernstam

Clin Cancer Res (2020) 26 (8): 1924–1931.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-0306

Published: 15 April 2020

View article

Includes: Supplementary data

Journal Articles

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

Gerald S. Falchook, Razelle Kurzrock, Hesham M. Amin, Wenyuan Xiong, Siqing Fu, Sarina A. Piha-Paul, Filip Janku, Ghazaleh Eskandari, Daniel V. Catenacci, Manfred Klevesath, Rolf Bruns, Uz Stammberger, Andreas Johne, Friedhelm Bladt, Manja Friese-Hamim, Pascal Girard, Samer El Bawab, David S. Hong

Clin Cancer Res (2020) 26 (6): 1237–1246.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-2860

Published: 13 March 2020

View article

Includes: Supplementary data

Journal Articles

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric-Bernstam, Josep Tabernero, Filip Janku, Leena Gandhi, A. John Iafrate, Darrell R. Borger, Nobuya Ishii, Youyou Hu, Yulia Kirpicheva, Valerie Nicolas-Metral, Anna Pokorska-Bocci, Anne Vaslin Chessex, Claudio Zanna, Keith T. Flaherty, Jose Baselga

Clin Cancer Res (2019) 25 (9): 2699–2707.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-1959

Published: 01 May 2019

View article

Includes: Supplementary data

Journal Articles

Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors

David S. Hong, Patricia LoRusso, Omid Hamid, Filip Janku, Muaiad Kittaneh, Daniel V.T. Catenacci, Emily Chan, Tanios Bekaii-Saab, Shirish M. Gadgeel, Robert D. Loberg, Benny M. Amore, Yuying C. Hwang, Rui Tang, Gataree Ngarmchamnanrith, Eunice L. Kwak

Clin Cancer Res (2019) 25 (8): 2403–2413.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-1341

Published: 15 April 2019

View article

Includes: Supplementary data

Journal Articles

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

Clin Cancer Res (2018) 24 (1): 181–188.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-2007

Published: 02 January 2018

View article

Includes: Supplementary data

Journal Articles

Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer

Clin Cancer Res (2017) 23 (18): 5648–5656.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-0291

Published: 14 September 2017

View article

Includes: Supplementary data

Journal Articles

Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act

Kenneth L. Kehl, Cheryl P. Fullmer, Siqing Fu, Goldy C. George, Kenneth R. Hess, Filip Janku, Daniel D. Karp, Shumei Kato, Cynthia K. Kizer, Razelle Kurzrock, Aung Naing, Shubham Pant, Sarina A. Piha-Paul, Vivek Subbiah, Apostolia M. Tsimberidou, David S. Hong

Clin Cancer Res (2017) 23 (15): 4155–4162.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-3027

Published: 01 August 2017

View article

Includes: Supplementary data

Journal Articles

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

Clin Cancer Res (2017) 23 (14): 3657–3666.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-2592

Published: 13 July 2017

View article

Includes: Supplementary data

Journal Articles

Bringing Blood-Based Molecular Testing to the Clinic

Filip Janku, Razelle Kurzrock

Clin Cancer Res (2016) 22 (22): 5400–5402.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-1769

Published: 14 November 2016

View article

Journal Articles

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

Philippe L. Bedard, Josep Tabernero, Filip Janku, Zev A. Wainberg, Luis Paz-Ares, Johan Vansteenkiste, Eric Van Cutsem, José Pérez-García, Anastasios Stathis, Carolyn D. Britten, Ngocdiep Le, Kirsten Carter, David Demanse, Denes Csonka, Malte Peters, Angela Zubel, Heidi Nauwelaerts, Cristiana Sessa

Clin Cancer Res (2015) 21 (4): 730–738.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-1814

Published: 16 February 2015

View article

Includes: Supplementary data

Journal Articles

Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic

Denis L.F. Jardim, Chad Tang, Debora De Melo Gagliato, Gerald S. Falchook, Kenneth Hess, Filip Janku, Siqing Fu, Jennifer J. Wheler, Ralph G. Zinner, Aung Naing, Apostolia M. Tsimberidou, Vijaykumar Holla, Marylin M. Li, Sinchita Roy-Chowdhuri, Raja Luthra, Ravi Salgia, Razelle Kurzrock, Funda Meric-Bernstam, David S. Hong

Clin Cancer Res (2014) 20 (24): 6336–6345.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-1293

Published: 14 December 2014

View article

Includes: Supplementary data

Journal Articles

Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic

Chad Tang, Kenneth Hess, Denis Leonardo F. Jardim, Debora De Melo Gagliato, Apostolia M. Tsimberidou, Gerald Falchook, Siqing Fu, Filip Janku, Aung Naing, Sarina Piha-Paul, Vivek Subbiah, Jennifer Wheler, Ralph G. Zinner, Razelle Kurzrock, Lee M. Ellis, Funda Meric-Berstam, David S. Hong

Clin Cancer Res (2014) 20 (23): 5956–5963.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-1582

Published: 30 November 2014

View article

Includes: Supplementary data

Journal Articles

Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses

Apostolia-Maria Tsimberidou, Sijin Wen, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Kenneth Aldape, Yang Ye, Razelle Kurzrock, Donald Berry

Clin Cancer Res (2014) 20 (18): 4827–4836.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-0603

Published: 14 September 2014

View article

Includes: Supplementary data

Journal Articles

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

Apostolia-Maria Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Rajyalakshmi Luthra, Yang Ye, Sijin Wen, Donald Berry, Razelle Kurzrock

Clin Cancer Res (2012) 18 (22): 6373–6383.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-1627

Published: 14 November 2012

View article

Includes: Supplementary data

Journal Articles

Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009

Filip Janku, Donald A. Berry, Jing Gong, Henrique A. Parsons, David J. Stewart, Razelle Kurzrock

Clin Cancer Res (2012) 18 (22): 6356–6363.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-0178

Published: 14 November 2012

View article

Includes: Supplementary data

NARROW

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor−positive Metastatic Breast Cancer or Other Solid Tumors

Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer

Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

Bringing Blood-Based Molecular Testing to the Clinic

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic

Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic

Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only